filmov
tv
Dr. Stinchcombe Discusses Differences in Toxicity Profiles Among ALK Inhibitors in NSCLC
Показать описание
OncLive
cancer
oncology
Рекомендации по теме
0:00:53
Dr. Stinchcombe Discusses Differences in Toxicity Profiles Among ALK Inhibitors in NSCLC
0:01:10
Dr. Stinchcombe on Advances in Targeted Therapies in NSCLC
0:00:51
Dr. Stinchcombe Discusses the PACIFIC Trial for NSCLC
0:00:52
Dr. Stinchcombe on the Benefit of Alectinib in ALK+ NSCLC
0:01:32
Dr. Stinchcombe on Remaining Challenges in ALK+ NSCLC
0:01:03
Dr. Thomas Stinchcombe on Targeted Therapies in Squamous Cell Lung Cancer
0:01:08
Dr. Stinchcombe on the KEYNOTE-189 Trial in Lung Cancer
0:00:56
Dr. Stinchcombe on the ALTA-1L Trial in ALK+ NSCLC
0:01:05
Dr. Stinchcombe on Molecular Testing in ALK+ NSCLC
0:01:51
Dr. Camidge Discusses Treatment of Patients With ALK+ NSCLC
0:01:42
Thomas E. Stinchcombe, MD
0:18:52
Expert Cancer Panel: mNSCLC, ALK+, w/ CNS progression and controlled systemic disease on alectinib
0:01:06
Dr Oliver Dorigo Discusses an Interdisciplinary Approach to Care in Gynecologic Oncology
0:07:55
Emerging Checkpoint Inhibitors for Lung Cancer
0:07:24
Debate: Surgery for stage IIIa patients with lung cancer? - No
0:01:34
Dr. Paul Discusses the Pulmonologist’s Role in Managing Patients With Lung Cancer
0:04:00
Alectinib eclipses crizotnib for ALK positive lung cancer
0:23:47
Diversity in Cancer Care | Lung Cancer | Challenges in Treatment
0:10:44
Immunotherapy: Simple in Theory
0:00:55
Dr. West on FDA Approval of Frontline Alectinib in ALK+ NSCLC
0:23:42
Current Status of Adjuvant Therapy for NSCLC
0:01:30
Dr. Fenske Discusses Disease Progression on Ibrutinib in MCL
0:01:55
Dr. Villaflor Discusses Alectinib in ALK+ NSCLC
0:02:28
Expert Discusses Promise of Abemaciclib for Breast Cancer Treatment
0:00:53
0:01:10
0:00:51
0:00:52
0:01:32
0:01:03
0:01:08
0:00:56
0:01:05
0:01:51
0:01:42
0:18:52
0:01:06
0:07:55
0:07:24
0:01:34
0:04:00
0:23:47
0:10:44
0:00:55
0:23:42
0:01:30
0:01:55
0:02:28